[go: up one dir, main page]

WO2009108360A3 - Inhibition de la croissance tumorale post-radique - Google Patents

Inhibition de la croissance tumorale post-radique Download PDF

Info

Publication number
WO2009108360A3
WO2009108360A3 PCT/US2009/001274 US2009001274W WO2009108360A3 WO 2009108360 A3 WO2009108360 A3 WO 2009108360A3 US 2009001274 W US2009001274 W US 2009001274W WO 2009108360 A3 WO2009108360 A3 WO 2009108360A3
Authority
WO
WIPO (PCT)
Prior art keywords
vasculogenesis
inhibition
inhibitor
post
tumor growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/001274
Other languages
English (en)
Other versions
WO2009108360A2 (fr
Inventor
John Martin Brown
G-One Ahn
Mitomu Kioi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Priority to EP09716057A priority Critical patent/EP2262494A2/fr
Priority to US12/919,654 priority patent/US20110091486A1/en
Publication of WO2009108360A2 publication Critical patent/WO2009108360A2/fr
Publication of WO2009108360A3 publication Critical patent/WO2009108360A3/fr
Anticipated expiration legal-status Critical
Priority to US14/089,141 priority patent/US20140086901A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/731—Carrageenans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des compositions et des procédés d'inhibition de la croissance de tumeurs solides à la suite d'une radiothérapie. Les compositions et les procédés ciblent des métalloprotéinases matricielles et des cellules dérivées de la moelle osseuse qui expriment des métalloprotéinases matricielles.
PCT/US2009/001274 2008-02-29 2009-02-27 Inhibition de la croissance tumorale post-radique Ceased WO2009108360A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP09716057A EP2262494A2 (fr) 2008-02-29 2009-02-27 Inhibition de la croissance tumorale post-radique par un inhibiteur de la vasculogenèse
US12/919,654 US20110091486A1 (en) 2008-02-29 2009-02-27 Inhibition of post-radiation tumor growth
US14/089,141 US20140086901A1 (en) 2008-02-29 2013-11-25 Inhibition of Post-Radiation Tumor Growth

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6765208P 2008-02-29 2008-02-29
US61/067,652 2008-02-29

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/919,654 A-371-Of-International US20110091486A1 (en) 2008-02-29 2009-02-27 Inhibition of post-radiation tumor growth
US14/089,141 Continuation-In-Part US20140086901A1 (en) 2008-02-29 2013-11-25 Inhibition of Post-Radiation Tumor Growth

Publications (2)

Publication Number Publication Date
WO2009108360A2 WO2009108360A2 (fr) 2009-09-03
WO2009108360A3 true WO2009108360A3 (fr) 2010-08-12

Family

ID=40908959

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/001274 Ceased WO2009108360A2 (fr) 2008-02-29 2009-02-27 Inhibition de la croissance tumorale post-radique

Country Status (3)

Country Link
US (1) US20110091486A1 (fr)
EP (2) EP2262494A2 (fr)
WO (1) WO2009108360A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012047339A2 (fr) * 2010-06-28 2012-04-12 The General Hospital Corporation Anti-cxcr4 en tant que sensibilisant à des agents de traitement d'un cancer
US9549953B2 (en) * 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
GB201320835D0 (en) * 2013-11-26 2014-01-08 Ucl Business Plc HIF inhibitors
KR20170132314A (ko) * 2015-04-02 2017-12-01 프록시머겐 리미티드 신규한 암 치료제

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064207A2 (fr) * 2000-03-01 2001-09-07 University Of South Florida Procedes permettant de moduler la resistance aux medicaments dont le mediateur est l'adhesion cellulaire

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2305787A1 (fr) * 2000-05-09 2001-11-09 The University Of British Columbia Traitement antagoniste cxcr4 de cellules hematopoietiques
US6949243B1 (en) * 1999-11-24 2005-09-27 Schering Corporation Methods of inhibiting metastasis
ES2368741T3 (es) * 2004-02-25 2011-11-21 Dana-Farber Cancer Institute, Inc. Inhibidores del receptor 1 del factor de crecimiento de tipo insulina para inhibir el crecimiento de células tumorales.
RU2008142775A (ru) * 2006-03-29 2010-05-10 Дженентек, Инк. (Us) Диагностика и лечение опухолей
CA2659337A1 (fr) * 2006-08-07 2008-02-14 Genzyme Corporation Therapie combinee
WO2010017083A1 (fr) * 2008-08-04 2010-02-11 Wayne State University Procédés de traitement du cancer par des anticorps cd11b

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064207A2 (fr) * 2000-03-01 2001-09-07 University Of South Florida Procedes permettant de moduler la resistance aux medicaments dont le mediateur est l'adhesion cellulaire

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
"Symposium", RADIOTHERAPY AND ONCOLOGY, ELSEVIER, vol. 88, 1 September 2008 (2008-09-01), pages S62 - S67, XP025961928, ISSN: 0167-8140, [retrieved on 20080901] *
ALGUR E ET AL: "Synergistic cytotoxic effects of zoledronic acid and radiation in human prostate cancer and myeloma cell lines", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, vol. 61, no. 2, 1 February 2005 (2005-02-01), pages 535 - 542, XP025261421, ISSN: 0360-3016, [retrieved on 20050201] *
CHRISTOPHER S GONDI ET AL: "Downregulation of uPA, uPAR and MMP-9 using small, interfering, hairpin RNA (siRNA) inhibits glioma cell invasion, angiogenesis and tumor growth", NEURON GLIA BIOLOGY,, vol. 1, no. 2, 1 January 2004 (2004-01-01), pages 176, XP002543013, ISSN: 1740-925X, [retrieved on 20041025] *
DAUBINE FLORENCE ET AL: "Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis", JOURNAL OF THE NATIONAL CANCER INSTITUTE (CARY), vol. 99, no. 4, February 2007 (2007-02-01), pages 322 - 330, XP002572682, ISSN: 0027-8874 *
DE PALMA MICHELE ET AL: "Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 9, no. 6, 1 June 2003 (2003-06-01), pages 789 - 795, XP002527465, ISSN: 1078-8956 *
GIRAUDO ENRICO ET AL: "An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis", JOURNAL OF CLINICAL INVESTIGATION, vol. 114, no. 5, September 2004 (2004-09-01), pages 623 - 633, XP002572683, ISSN: 0021-9738 *
GOGINENI VENKATESWARA RAO ET AL: "RNAi-mediated downregulation of radiation-induced MMP-9 leads to apoptosis via activation of ERK and Akt in IOMM-Lee cells", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 34, no. 1, January 2009 (2009-01-01), pages 209 - 218, XP002572680, ISSN: 1019-6439 *
GROVES MORRIS D ET AL: "Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme.", JOURNAL OF CLINICAL ONCOLOGY : OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY 1 MAR 2002, vol. 20, no. 5, 1 March 2002 (2002-03-01), pages 1383 - 1388, XP002572679, ISSN: 0732-183X *
HIRAGA T ET AL: "Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 10, 1 January 2004 (2004-01-01), pages 4559 - 4567, XP003020896, ISSN: 1078-0432 *
KIOI ET AL: "Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice", THE JOURNAL OF CLINICAL INVESTIGATION, vol. 120, no. 3, 1 March 2010 (2010-03-01), pages 694 - 705, XP002572686, Retrieved from the Internet <URL:http://www.jci.org/articles/view/40283/pdf> [retrieved on 20100311], DOI: 10.1172/JCI40283 *
LAGGNER U ET AL: "Regression of melanoma metastases following treatment with the n-bisphosphonate zoledronate and localised radiotherapy.", CLINICAL IMMUNOLOGY (ORLANDO, FLA.) JUN 2009, vol. 131, no. 3, 27 February 2009 (2009-02-27), pages 367 - 373, XP002572685, ISSN: 1521-7035 *
LONDON CARLA A ET AL: "A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.", CANCER GENE THERAPY, vol. 10, no. 11, November 2003 (2003-11-01), pages 823 - 832, XP002572681, ISSN: 0929-1903 *
MOELLER BENJAMIN J ET AL: "Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity", CANCER CELL, vol. 8, no. 2, August 2005 (2005-08-01), pages 99 - 110, XP002572678, ISSN: 1535-6108 *
MOELLER BENJAMIN J ET AL: "Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: Role of reoxygenation, free radicals, and stress granules", CANCER CELL, vol. 5, no. 5, May 2004 (2004-05-01), pages 429 - 441, XP002572677, ISSN: 1535-6108 *
SHI Z ET AL: "Enhanced effectiveness of a novel MMP inhibitor, prinomastat (AG3340) with radiotherapy (RT) in a glioma model", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, no. 41, March 2000 (2000-03-01), & 91ST ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH.; SAN FRANCISCO, CALIFORNIA, USA; APRIL 01-05, 2000, pages 326, XP001525114, ISSN: 0197-016X *
WOOD JEANETTE ET AL: "Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 302, no. 3, September 2002 (2002-09-01), pages 1055 - 1061, XP002572684, ISSN: 0022-3565 *

Also Published As

Publication number Publication date
EP2262494A2 (fr) 2010-12-22
EP2649995A2 (fr) 2013-10-16
WO2009108360A2 (fr) 2009-09-03
EP2649995A3 (fr) 2014-05-21
US20110091486A1 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2011103016A3 (fr) Compositions et méthodes d&#39;inhibition d&#39;ezh2
HK1210611A1 (en) Histone demethylase inhibitors
WO2010011296A3 (fr) Inhibiteurs de désacétylase et leurs utilisations
WO2010045586A3 (fr) Peptides à domaine cytoplasmique muc-1 en tant qu&#39;inhibiteurs du cancer
WO2009114703A3 (fr) Thérapie combinée pour le traitement d&#39;un cancer
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
HK1245677A1 (zh) 用於治疗炎症和癌症的杂环itk抑制剂
EA200900819A1 (ru) Хиназолины для ингибирования pdk1
WO2010000364A8 (fr) Dérivé de pyrrolopyridinylpyrimidin-2-ylamine
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d&#39;autres cancers déficients en p53
CL2012003680A1 (es) Compuestos derivados de (1,8) naftiridinas 2,4 diaril sustituidas inhibidores de quinasas; su procedimiento de obtencion; composicion farmaceutica; y su uso para el tratamiento y/o prevencion de cancer, tumor, tumores malignos, entre otros; kit farmaceutico.
WO2012015914A3 (fr) Modificateurs du récepteur d&#39;hydrocarbure aryle (ahr) en tant que nouveaux produits thérapeutiques anticancéreux
WO2013023084A3 (fr) Procédés et compositions pour l&#39;inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc
PH12013502370A1 (en) Multiheteroaryl compounds as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
WO2011146879A3 (fr) Procédés et compositions liés à la modulation de l&#39;autophagie
MX2010005768A (es) Composiciones y métodos para inhibir la activación del arnbc-dependiente de la proteina de la kinasa y la inhibición del crecimiento tumoral.
WO2010048144A3 (fr) Procédés d’imagerie et de radiothérapie
ZA201301177B (en) Nucleic acids,compositions and methods for the excision of target nucleic acids
EP4442318A3 (fr) Inhibiteurs hétérocycliques de mct4
WO2011127465A3 (fr) Inhibiteurs de ship et leurs utilisations
MX2013001150A (es) Marcadores de peso molecular de acetato glatiramero.
WO2012037547A3 (fr) Méthodes et compositions utilisées pour inhiber l&#39;autophagie dans le traitement de la fibrose
WO2009108360A3 (fr) Inhibition de la croissance tumorale post-radique
WO2009114470A3 (fr) Tétrahydroindole et tétrahydroindazole utilisés comme inhibiteurs de hsp90, contenant un fragment de liaison à du zinc
WO2011130697A3 (fr) Ciblage tissulaire

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09716057

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009716057

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12919654

Country of ref document: US